Clinical Efficacy of Trimetazidine and Holistic Management in the Treatment of Coronary Heart Disease
AbstractAbstract Background: To investigate the clinical efficacy of trimetazidine and holistic management in the treatment of coronary heart disease. Methods: A total of 128 cases of patients with coronary heart disease were admitted in The Second Affiliated Hospital of Dalian Medical University from October 2014 to June 2017. These patients were divided into control group and experimental group, with 64 patients each. The patients in the control group underwent conventional treatment. On this basis, the patients in the experimental group were treated with trimetazidine. Both groups underwent holistic management. The clinical conditions, echocardiography indexes, life quality, and mental states of patients were compared between the two groups. Results: The total efficient rate of patients in the control group was significantly lower than that of the experimental group, and the difference was statistically significant (P<0.05). After treatment, the left ventricular ejection fraction of patients in the experimental group was higher than that of the control group; the left ventricular end diastolic diameter and left ventricular posterior wall thickness of patients in the experimental group were lower than those of the control group, and the differences were statistically significant (P<0.05). The physiological health score, mental health score, Hamilton Depression Scale and Hamilton Anxiety Rating Scale of patients were significantly decreased compared with the control group, and the differences were statistically significant (P<0.05). Conclusion: The efficacy of trimetazidine in the treatment of coronary heart disease is definite. The assisting holistic management can significantly improve the mental status and life quality of patients by enhancing the cardiac function, which has clinical reference and promotion values.
Chrusciel P, Rysz J, Banach M (2014). De-fining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs, 74(9): 971-980.
Dézsi CA (2014). Trimetazidine in Practice: Review of the clinical and experimental evidence. Am J Ther, 23(3): e871-e879.
Wakuno A, Maeda T, Kodaira K, Kikuchi T, Ohta M (2017). Anesthetic management with sevoflurane combined with alfax-alone-medetomidine constant rate infu-sion in a Thoroughbred racehorse un-dergoing a long-time orthopedic surgery. J Equine Sci, 28(3): 111-115.
Abdelbary A, Elgazayerly ON, Elgendy NA, Ali AA (2010). Floating tablet of trimeta-zidine dihydrochloride: an approach for extended release with Zero-Order kinet-ics. AAPS PharmSciTech, 11(3): 1058–1067.
Cavar M, Ljubkovic M, Bulat C et al (2016). Trimetazidine does not alter metabolic substrate oxidation in cardiac mitochon-dria of target patient population. Br J Pharmacol, 173(9): 1529-1540.
Kumral TL, Yıldırım G, Berkiten G, Saltürk Z, Ataç E, Atar Y, Uyar Y (2016). Effica-cy of trimetazidine dihydrochloride for relieving chronic tinnitus: a randomized double-blind study. Clin Exp Otorhinolaryn-gol, 9(3): 192-197.
Mallick P, Taneja G, Moorthy B, Ghose R (2017). Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions. Expert Opin Drug Metab Toxicol, 13(6): 605-616.
Kones R (2011). Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatinin management. Drug Des Devel Ther, 5: 325-380.
Zhang Q, Polyakov NE, Chistyachenko YS, Khvostov MV, Frolova TS, Tolstikova TG , Dushkin AV, Su W (2018). Experi-mental study on curcumin inhibiting pro-liferation and invasion of human oste-osary. Drug Deliv, 25(1): 198-209.
Plagisou L, Tsironi M, Zyga S, Moisoglou I, Maniadakis N, Prezerakos P (2015). As-sessment of nursing staff's theoretical knowledge of cardiovascular resuscitation in an NHS public hospital. Hellenic J Car-diol, 56(2): 149-153.
Masic I, Rahimic M, Dilic M, Kadribasic R, Toromanovic S (2011). Socio-medical characteristics of coronary disease in bosnia and herzegovina and the world. Mater Sociomed, 23(3): 171-183.